Genentech, a member of the Roche Group, announced that new data from early and late-stage clinical studies on more than 19 approved and investigational cancer medicines, will be presented at the 2018 American Society of Clinical Oncology, or ASCO, Annual Meeting, taking place from June 1-5 in Chicago. More than 90 abstracts have been accepted across 13 cancer types, including two “late breakers” and 15 oral presentations. “New data to be presented from our industry-leading oncology portfolio, including lung and hematology programs, will demonstrate how our science-driven approach aims to improve outcomes for people living with cancer,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “At ASCO, we look forward to sharing our progress and commitment to build the future of personalized healthcare in oncology.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.